Clinical Trials Logo

Stimulant Dependence clinical trials

View clinical trials related to Stimulant Dependence.

Filter by:
  • None
  • Page 1

NCT ID: NCT04449055 Completed - Clinical trials for Methamphetamine-dependence

Pilot TMS for Methamphetamine Use Disorder

Start date: October 6, 2020
Phase: N/A
Study type: Interventional
Read more »
NCT ID: NCT03485417 Recruiting - Clinical trials for Schizophrenia and Related Disorders

Substance Misuse To Psychosis for Stimulants

Start date: June 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

In Hong Kong, less than 5% of stimulants abusers were reported to misuse these substances via injection. Also, it is well known that patients with co-morbid substance abuse/dependence and psychosis or schizophrenia-related disorders are prone to earlier treatment discontinuation and high oral medication non-adherence, resulting in poorer overall outcomes. With the recent availabilities of the 4-weekly long-acting injectable form of aripiprazole, and the 4-weekly and the 3-monthly long-acting injectable form of paliperidone palmitate, on the background of the surging phenomenon of stimulant misuses in Hong Kong, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with substance use disorders with psychosis to develop into a more chronic disabling dependence or co-morbid state.

NCT ID: NCT03470480 Recruiting - Clinical trials for Substance Use Disorders

rTMS for Craving in Methamphetamine Use Disorder

Start date: February 7, 2018
Phase: N/A
Study type: Interventional
Read more »
NCT ID: NCT01863251 Completed - Opiate Dependence Clinical Trials

Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia

Start date: May 2013
Phase: Phase 2
Study type: Interventional

To evaluate the tolerability, acceptability and potential effect size of the efficacy of 4 months of atomoxetine treatment for patients with co-occurring ATS and heroin dependence (COATS) receiving buprenorphine maintenance treatment (BMT) and educational drug and HIV risk reduction counseling (EDRC).

NCT ID: NCT01094223 Completed - Clinical trials for Stimulant Dependence

Mindfulness Based Relapse Prevention for Stimulant Users

MBRP
Start date: April 2010
Phase: N/A
Study type: Interventional

The broad, long-term objective of the current research is to improve treatment for stimulant use disorders by augmenting traditional relapse prevention therapy with innovative meditation-based strategies to promote affect regulation skills. Based on Mindfulness-Based Cognitive Therapy for depression (Segal, Teasdale, & Williams, 2002), Marlatt and colleagues recently developed a manualized intervention for the treatment of substance using populations: Mindfulness Based Relapse Prevention (MBRP). The specific aims of this research are 1) To conduct a pilot randomized clinical trial to assess the feasibility of recruiting and retaining individuals for a large scale study and to determine the effect size of MBRP relative to a health education (ED) control group in stimulant users receiving contingency management (CM).

NCT ID: NCT00842036 Completed - Alcohol Dependence Clinical Trials

CRAFT Behavior Therapy: Treatment Entry Component

Start date: January 2006
Phase: Phase 2
Study type: Interventional

This research compares the benefits of the original treatment, Community Reinforcement and Family Training (CRAFT), with the Treatment Entry Training (TEnT) component of CRAFT to determine if TEnt alone can produce the primary outcome of CRAFT -- treatment entry of the drug user. We also look at the impact on the well-being of the concerned significant other and the drug use of their loved one.

NCT ID: NCT00628927 Completed - Clinical trials for Stimulant Dependence

An Eval of Neurocognitive Function, Oxidative Damage, and Their Association With Outcomes in METH and Cocaine Abusers.

Start date: February 2008
Phase: Phase 3
Study type: Observational

The purpose of this study is to determine whether performance on neurocognitive measures predicts treatment outcomes in individuals with substance abuse disorders. A second purpose is to compare the risk of damage, as well as actual damage, to DNA and other cell parts in people with substance abuse disorders to that of people who do not have substance abuse disorders.